Suzhou Ribo Life Science Re-files IPO Prospectus on HKEX, Highlighting Its Leadership in China's Small Nucleic Acid Therapeutics

Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted must be authorized.

Recently,Suzhou Ribo Life Science Co., Ltd.TechnologySuzhou Ribo Life Science Co., Ltd. submitted its IPO prospectus to the Hong Kong Stock Exchange in China.

The founding team, including Dr. Liang Zicai, Ms. Mo Hua, Professor Xi Zhen, and Professor Zhang Lihe, acted in concert, collectively controlling approximately 30.84% of the shares.

2023Year12In the month, Ribo Life Science granted Qilu Pharmaceutical the rights to develop, manufacture, and commercialize in mainland China, Hong Kong, and Macao.RBD7022The exclusive rights.

Ribo Life Science has also reached a new drug BD development cooperation with BI in the MASH field.According to the terms of the cooperation between the two parties,Ribo will also receive a sum ofAdvance PaymentIn addition, in this multi-target collaboration project, Ribo will be entitled to receive milestone payments based on the conduct of clinical studies, drug registration, and commercial success, as well as tiered sales royalties from marketed products, with the total transaction amount exceeding 2 billion US dollars.

Attached, download link, copy to browser:

https://www1.hkexnews.hk/app/sehk/2025/107314/documents/sehk25042504213_c.pdf。

More pharmaceutical companies' information cooperation and exchange can leave business cards in the backstage.